Oxford Sciences Innovation is a science business builder that works with academics to commercialise research and build companies based on Oxford science.
Charles brings investment, executive, and board experience from roles including CEO of Oxford Sciences Innovation, co-founder of Monograph Capital, and chair of Patagonia.
Matt brings financial and investment experience from roles at Mind Foundry, Oxford Science Enterprises, and Goldman Sachs. He serves as chief financial officer at Fractile.
The Series B round was led by the Blue Venture Fund to accelerate the deployment of artificial intelligence in echocardiography.
"Echocardiograms uploaded to the cloud and analyzed by artificial intelligence are set to revolutionize cardiac disease treatment pathways by helping more people understand their risk of heart disease earlier and with greater accuracy,"
The financing round was led by Oxford Sciences Innovation to support the company in expanding its peptide discovery operations.
"Orbit’s team has the right combination of scientific rigor and novel peptide technologies to lead a new generation of drug development, and we look forward to partnering with the team to advance their mission,"
Oxford Sciences Innovation led the seed investment, which will fund commercialisation and technological advancement.
"The world must create 70% more food by 2050 in a sustainable way. We need to double production, improve efficiencies on existing farmland, and avoid destroying more rainforests. At Omega Crop we can monitor and evaluate vast tracts of farmland, diagnosing crop loss events at scale and enable targeted interventions that will help feed our growing world."
The financing round was led by Vulpes Investment Management with backing from existing investors to fund first in-human data acquisition.
"The current device market for brain aneurysms is valued at well over $1bn and is growing rapidly year-on-year. One of the biggest challenges when it comes to treating neurovascular disease is having devices with high efficacy whilst minimising adverse events. Studies show that often multiple attempts are made to place treatment devices, as they often have challenges of landing accurately, opening and maintaining position. This can lead to adverse events and multiple devices being used. Procedures typically cost over $50,000 to treat a brain aneurysm and a next generation flow diverter overcoming unmet needs, offers the chance for more effective, safer and cost effective treatments as well as allowing many more patients to benefit. We plan to use this funding to bring Oxford Endovascular’s ground-breaking technology to the next stage and gain clinical data from human studies."
The University of Oxford spinout secured £10.4m from backers including Parkwalk Advisors and Oxford Sciences Innovation to expand its presence in the insurance sector.
"There are some technologies that can change a small part of the insurance value chain, but there are no technology companies that can help insurers transform the entire insurance operation. Therefore, we had been seeking a reliable partner with first-class technology in order to jointly develop such solutions across the insurance value chain."
The financing round was led by Foresight Williams Technology to support product rollout and grid balancing services.
"This round comes at an exciting time in markets across the UK, Western Europe and North America. With recent pledges to transition from natural gas in new build properties by 2025 across Europe along with unprecedented volatility in the UK’s electricity balancing market, Mixergy is well positioned to accelerate the low carbon transition through relationships with low cost manufacturing supply chains that cater to a global market."
The funding round was led by Parkwalk Advisors, Universal Partners, Oxford Sciences Innovation and Inovia Capital to support customer demand and company growth.
"We have been tracking YASA’s progress for a number of years and are pleased to have the opportunity to invest in one of the UK’s most exciting high-growth technology companies that is well positioned to take advantage of the rapid move to electrification in both automotive and aerospace sectors."
The Oxford-based crop protection firm secured the financing from co-leads Oxford Sciences Innovation and Parkwalk Advisors.
"Weeds are now a greater threat to crop yields than at any time in recent decades. New solutions are urgently needed. Raising £6m at this stage in the company’s development is a real testament to the strength of the company’s prospects."
The financing round was led by RT Capital Management alongside the Oxford Technology and Innovations EIS Fund.
"Over the last few years Zegami has been developing a cutting edge Visual Data Exploration platform to democratise data analytics, enabling people to make sense of the tsunami of data available today."